is the repeated voiding of urine into clothing or bedding in a child old enough that continence is developmentally expected, and it is one of the most common reasons families seek pediatric mental health input. places enuresis among the elimination disorders, requires a chronological age of at least 5 years (or equivalent developmental level), and recognizes nocturnal-only, diurnal-only, and combined subtypes. Most cases are primary monosymptomatic nocturnal enuresis in otherwise typically developing children, with a strong familial pattern, a high spontaneous remission rate, and a small but real burden of shame, sleep disruption, and family conflict. First-line management pairs demystifying education and conservative measures with the for sustained response, reserving for short-term need or alarm non-response. The clinical bottom line: rule out medical and behavioral mimics, set expectations from the family's perspective, and choose between alarm and desmopressin based on motivation, sleep arousal, and tolerance of relapse.
Enuresis is common in early school-age children and declines steeply with age, but a meaningful minority persist into adolescence and adulthood. The clinical implication is that prevalence figures depend heavily on the age cutoff, the subtype counted, and whether frequency thresholds match DSM-5-TR.1-2
Prevalence by age
- Approximately 5-10% of 7-year-olds meet criteria for nocturnal enuresis, falling to roughly 1.5-3% at age 10 and below 1% in late adolescence.1,3
- Spontaneous remission is approximately 15% per year of untreated children.3
- Daytime (diurnal) enuresis is less common, affecting about 2-4% of school-age children, and is more common in girls than boys.2,4
Sex and familial distribution
- Nocturnal enuresis is approximately 1.5-2 times more common in boys than girls in the preschool and early school years; the sex ratio narrows with age.1,3
- About two-thirds of children with nocturnal enuresis have a first-degree relative with a history of the disorder, and concordance is higher in monozygotic than dizygotic twins.5
Comorbidity and risk factors
- is the most consistently associated psychiatric comorbidity, with prevalence in enuretic children roughly 2-3 times that of the general pediatric population.6
- Constipation and functional bladder disturbances coexist in a substantial minority and are an important treatment-modifying finding.7
- Obstructive sleep apnea, low socioeconomic status, parental separation, and a history of stressful life events have been associated with enuresis, particularly with secondary enuresis.2,7
- Developmental delay, , and intellectual disability increase risk and complicate the developmental-age threshold required for diagnosis.2
Primary monosymptomatic nocturnal enuresis is best understood as a mismatch between nocturnal urine production, bladder reservoir function, and arousal from sleep. The three-system model (high arousal threshold + nocturnal polyuria + reduced functional bladder capacity) accounts for most cases and guides treatment selection.8
Nocturnal polyuria
- A blunted nocturnal rise in arginine leads to higher overnight urine output exceeding bladder capacity in many children with nocturnal enuresis.8-9
- This subgroup is the population most likely to respond to desmopressin.9
Bladder dysfunction
- A reduced nocturnal functional bladder capacity, sometimes with detrusor overactivity, characterizes another subgroup, especially children with daytime urgency or frequency.8
- These children tend to respond less well to desmopressin alone and may benefit from anticholinergics or urotherapy.7-8
Arousal
- Children with enuresis demonstrate a higher arousal threshold from sleep; brainstem and pontine micturition center maturation appears delayed.8,10
- This is the rationale for the enuresis alarm, which conditions arousal to the sensation of a full bladder.10
Genetics
- Heritability estimates approach 70%, with linkage signals on chromosomes 12q, 13q, and 22q11 in some pedigrees.5
- Inheritance is typically polygenic; high-penetrance autosomal-dominant patterns are described but uncommon.5
Secondary enuresis
- Defined as recurrence after at least 6 months of continence, secondary enuresis is more often associated with psychosocial stressors, urinary tract infection, new-onset constipation, diabetes mellitus or insipidus, sleep-disordered breathing, and child maltreatment.2,7
POP-BAR
Polyuria (nocturnal), Overactive bladder, Poor arousal — three drivers of nocturnal enuresis; tailor treatment to which one dominates.
DSM-5-TR situates enuresis among the elimination disorders and frames it as a developmentally inappropriate, sufficiently frequent voiding pattern that cannot be explained by a medical cause or a substance. The criteria are deliberately permissive about intent (voluntary or involuntary) so as not to penalize children with low arousal.11
DSM-5-TR criteria
- Repeated voiding of urine into bed or clothes, whether involuntary or, less commonly, intentional.11
- Frequency of at least twice per week for at least 3 consecutive months, or symptoms producing clinically significant distress or impairment in social, academic, or other important areas.11
- Chronological age of at least 5 years, or an equivalent developmental level.11
- The behavior is not attributable to the physiological effects of a substance (for example, a diuretic, antipsychotic) or another medical condition (for example, diabetes, spina bifida, seizure disorder).11
Subtypes (specify)
- Nocturnal only: voiding only during nighttime sleep, typically in the first third of the night.11
- Diurnal only: voiding during waking hours.11
- Nocturnal and diurnal: both patterns present.11
Primary versus secondary
- Primary enuresis refers to children who have never achieved sustained urinary continence (often defined as 6 consecutive dry months).2,11
- Secondary enuresis refers to recurrence after a sustained dry period and more often signals a medical, behavioral, or psychosocial trigger.2,7
ICD-11 differences
- lists enuresis under 'Elimination disorders' (6C00) and similarly requires age >=5 years or equivalent developmental level.12
- ICD-11 explicitly subtypes nocturnal, diurnal, and mixed forms, mirroring DSM-5-TR; it does not require the twice-weekly frequency threshold and instead emphasizes clinical significance.12
The 5-year age threshold is chronological, not absolute — a child with a developmental level below 5 years does not meet criteria regardless of birth age.11
Most children present with primary monosymptomatic nocturnal enuresis: a typically developing child, dry by day, with no daytime urinary symptoms, who wets the bed several nights per week. The presentation diverges meaningfully once daytime symptoms, constipation, or behavioral comorbidities are added to the picture.7-8
Prototypical presentation
- A school-age child, often male, with a family history, deep sleeper, who wets the bed in the first third of the night with a single large void.3,8
- The child is otherwise well, growth and development are normal, and daytime continence is intact.7
- Families typically describe difficulty waking the child even with effort.8
Non-monosymptomatic features (red flags for bladder dysfunction):
- Daytime urgency, frequency (>7 voids per day), holding maneuvers (Vincent's curtsy), or daytime incontinence.7
- Weak or interrupted stream, straining, or a sensation of incomplete emptying.7
- Recurrent urinary tract infections.7
- These features point toward an overactive bladder or dysfunctional voiding and require urotherapy-led management.7
Constipation overlap
- Functional constipation coexists with enuresis in a substantial subset; rectal distension reduces functional bladder capacity and worsens detrusor overactivity.7
- Treating constipation first can resolve enuresis without further intervention in some children.7
Course and trajectory
- Primary nocturnal enuresis typically remits at approximately 15% per year without intervention.3
- A small percentage of children (roughly 1-2%) continue to have nocturnal enuresis into adulthood; risk is higher with severe pediatric frequency and family history.1,3
- Secondary enuresis carries a higher rate of comorbid psychiatric and medical findings and is less likely to remit without addressing the precipitant.2,7
Functional impact
- Children with enuresis report lower self-esteem, social withdrawal around sleepovers and camp, and shame; effective treatment reverses much of this.13
- Family stress, sibling teasing, and punitive parental responses are common and worth screening for.13
Voiding diaries kept for 1-2 weeks (daytime voids, fluid intake, wet/dry nights, bowel pattern) clarify subtype, capture polyuria, and quantify baseline severity before any pharmacotherapy.7
Enuresis is a clinical diagnosis but a diagnosis of exclusion in important respects: medical and behavioral mimics are common enough that every initial evaluation must screen for them. Secondary enuresis raises the prior probability of an organic cause meaningfully.2,7
Urologic and renal
- Urinary tract infection — particularly in girls and in any child with new-onset daytime symptoms or dysuria; obtain urinalysis and culture.7
- Posterior urethral valves, ectopic ureter (constant dampness in girls), neurogenic bladder, and bladder outlet obstruction — suggested by abnormal stream, recurrent infection, or neurologic signs.7
- Chronic kidney disease with concentrating defects.7
Endocrine and metabolic
- Diabetes mellitus — polyuria, polydipsia, weight loss; check urine glucose and serum glucose.7
- Diabetes insipidus, central or nephrogenic — large-volume dilute urine, often with daytime polyuria.7
- Hypercalcemia and hypokalemia (concentrating defects).7
Neurologic
- Spinal dysraphism (occult spina bifida, tethered cord) — sacral dimple, hair tuft, lower-extremity neurologic asymmetry, gait change.7
- Nocturnal seizures — stereotyped events, tongue biting, postictal confusion.7
- Obstructive sleep apnea — habitual snoring, mouth breathing, adenotonsillar hypertrophy; OSA can cause or worsen enuresis and may resolve with adenotonsillectomy.14
Behavioral and psychiatric
- ADHD — increases risk of enuresis and complicates alarm therapy through poor adherence.6
- Anxiety, depression, or PTSD — particularly in secondary enuresis after a stressor.2,13
- Constipation with overflow incontinence and dysfunctional voiding.7
- Child maltreatment, including sexual abuse, should be considered in secondary or atypical presentations, particularly when behavioral regression accompanies the change.2
Substance and iatrogenic
- Diuretics, (nephrogenic diabetes insipidus), valproate, antipsychotics (particularly ), , and methylphenidate (rarely) have all been implicated.7,15
DIFFERENTIAL versus normal development
- Children younger than 5 years (chronological or developmental) do not meet criteria; bedwetting in a 4-year-old is developmentally typical and warrants reassurance rather than diagnosis.11
The evaluation is largely a structured history and physical examination supported by a urinalysis; further testing is driven by specific findings. The goal is to identify subtype, rule out organic causes, screen for constipation and OSA, and quantify severity.7-8
History essentials
- Wet nights per week, time of night, single versus multiple voids, volume.7
- Daytime voiding pattern, frequency, urgency, holding maneuvers, stream quality, continence.7
- Fluid intake pattern, especially evening intake of water, milk, and caffeinated beverages.7
- Bowel pattern using Bristol stool scale and frequency; explicitly ask about soiling.7
- Sleep history, snoring, witnessed apneas, daytime sleepiness.14
- Family history of enuresis, age of resolution in affected relatives.5
- Developmental, school, and behavioral screen including ADHD and mood symptoms.6,13
- Psychosocial review: stressors, recent moves or losses, family conflict, and safety screen for maltreatment when indicated.2
Physical exam
- Growth parameters and blood pressure.7
- Abdominal exam for stool burden or palpable bladder.7
- External genitourinary exam for anatomic abnormalities and signs of irritation.7
- Lumbosacral inspection for midline cutaneous markers of dysraphism; lower-extremity neurologic exam including reflexes and gait.7
- ENT exam for adenotonsillar hypertrophy when OSA is suspected.14
Investigations - first line
- Urinalysis with specific gravity and dipstick for glucose, leukocytes, nitrites, and protein on every child.7
- Urine culture if symptomatic or urinalysis suggests infection.7
- Voiding diary for at least 7-14 days including wet/dry nights, daytime voids, and fluid intake.7
Investigations - second line (driven by red flags):
- Renal and bladder ultrasound for daytime symptoms, recurrent UTI, or abnormal stream.7
- Uroflowmetry with post-void residual for suspected dysfunctional voiding.7
- MRI spine for suspected dysraphism.7
- Polysomnography for suspected obstructive sleep apnea.14
- Serum glucose, electrolytes, calcium, and creatinine when polyuria is prominent.7
Validated rating scales and tools
- The (DVSS) and the International Children's Continence Society standardize symptom capture.7
- The or similar behavioral screen helps identify comorbid ADHD, anxiety, and mood symptoms that affect treatment selection and adherence.6,13
What NOT to order routinely
- Voiding cystourethrogram, urodynamics, and cystoscopy are not first-line studies and are reserved for specific urologic indications.7
- Routine bloodwork is not required for monosymptomatic nocturnal enuresis without polyuria or other red flags.7
WET BED
Weight (growth)/UA, Evening fluids, Toileting habits, Bowels/Bristol, , Daytime symptoms — the six-line first-visit history for any enuresis evaluation.
Treatment proceeds in steps: demystify and address modifiable factors (constipation, fluids, OSA) before any specific therapy, then choose between the enuresis alarm and desmopressin based on family preference, motivation, and clinical features. The alarm produces the most durable response; desmopressin is faster but with higher relapse off treatment.7-8,16
Step 1 - Education and conservative measures:
- Reframe enuresis as a developmental delay in arousal and urine-concentrating mechanisms, not a behavioral failure; explicitly discourage punishment, which worsens shame without improving wetting.7,13
- Limit evening fluids (no fluids in the last 1-2 hours before bed) while ensuring adequate daytime intake.7
- Avoid evening caffeine and excessive milk.7
- Regular daytime voiding schedule (every 2-3 hours) and complete bladder emptying before bed.7
- Treat constipation aggressively if present, typically with polyethylene glycol and a maintenance phase; resolution of constipation alone can resolve enuresis in some children.7
- Reward dry-night charts for younger children may help when paired with other measures.7
Pharmacotherapy
Strong evidence supports desmopressin as the most effective short-term pharmacologic option for monosymptomatic nocturnal enuresis, particularly in children with documented nocturnal polyuria.9,16
- Desmopressin: synthetic vasopressin analog acting on V2 receptors; reduces nocturnal urine output.9
- Oral lyophilisate (melt) 120-240 mcg at bedtime, or oral tablet 0.2-0.6 mg at bedtime; intranasal formulations are no longer recommended for enuresis because of hyponatremia risk and were the subject of an FDA safety communication.9,17
- Onset within hours; about 30% of children achieve full response and another 40% partial response.16
- High relapse rate (approximately 60-70%) on abrupt withdrawal; structured tapering improves sustained dryness.9,16
- Fluid restriction from 1 hour before to 8 hours after dosing is essential to avoid hyponatremia.17
- Anticholinergics (oxybutynin, tolterodine) are commonly recommended as add-on therapy for children with non-monosymptomatic enuresis and detrusor overactivity, often combined with desmopressin or urotherapy.7-8
- Tricyclic antidepressants (imipramine) have moderate evidence for nocturnal enuresis but are largely reserved for treatment-resistant cases because of cardiotoxicity in overdose; baseline EKG, family screen for arrhythmia and sudden cardiac death, and careful supply management are required.16
Desmopressin carries a risk of symptomatic hyponatremia and seizures, particularly when fluid intake is not restricted; counsel families explicitly and hold doses during illness with vomiting or excess fluid intake.17
Imipramine overdose is a leading cause of pediatric tricyclic-related cardiac death; dispense in small quantities and keep secured at home.16
Psychotherapy and behavioral
The enuresis alarm is the intervention with the most durable evidence of cure and remains first-line behavioral therapy for monosymptomatic nocturnal enuresis in motivated families.10,16
- Enuresis alarm: a moisture-sensitive sensor (bedside or wearable) triggers an alarm at the first drops of urine, conditioning arousal to bladder fullness.10
- Use nightly for at least 6-8 weeks; expect initial response over 4-6 weeks.10
- Full response in approximately 50-70% of children with appropriate selection and adherence.10,16
- Sustained dryness after discontinuation is roughly 40-50%, substantially higher than after desmopressin withdrawal.16
- Continue at least 14 consecutive dry nights before stopping; restart if relapse occurs.10
- Overlearning (increased evening fluid intake during the final weeks of successful therapy) reduces relapse in some protocols.10
- Dry-bed training, full-spectrum home training, and lifting (waking the child to void) have limited supporting evidence compared with alarm alone.16
- addresses comorbid anxiety, shame, and adherence rather than enuresis itself; it is supportive, not primary.13
Neuromodulation
- Transcutaneous electrical nerve stimulation (TENS) of the sacral or posterior tibial nerve has limited evidence for overactive bladder symptoms and refractory non-monosymptomatic enuresis.18
- Sacral neuromodulation is reserved for highly refractory cases with confirmed neurogenic bladder, evaluated in specialist centers.18
Adjunctive
- Treat coexisting constipation, OSA, and ADHD before declaring treatment failure; addressing these conditions can resolve apparently refractory enuresis.6-7,14
- Combination therapy (alarm plus desmopressin) is suggested by limited evidence to outperform either alone in selected children, particularly those with both polyuria and high arousal threshold.16
- Refer to pediatric urology for non-monosymptomatic enuresis, persistent symptoms despite first-line therapy, or any anatomic or neurologic red flag.7
Treatment-resistant pathway
- Reconfirm diagnosis, re-screen for constipation, OSA, and bladder dysfunction, and verify adherence and technique with the alarm.7
- Trial of combined alarm + desmopressin if not previously used together.16
- Anticholinergic add-on for documented detrusor overactivity.7
- Imipramine in adolescents with adequate cardiac screening, careful supply management, and shared decision-making.16
- Refer for specialist urodynamic evaluation.7
ABCDE for refractory enuresis
Alarm adherence, Bowels (constipation), Capacity (bladder), Daytime symptoms, Endocrine (DI/DM) — recheck each before declaring failure.
| Intervention | Evidence base/Comparator | Benefits | Harms | Certainty | Notes |
|---|---|---|---|---|---|
| Enuresis alarm | Cochrane reviews; multiple RCTs vs no treatment and vs desmopressin | Dry-night rates 50-70%; durable response after discontinuation (40-50% sustained dry) | Sleep disruption for child and family; high dropout if poor motivation | moderate | First-line behavioral therapy for monosymptomatic nocturnal enuresis in motivated families |
| Desmopressin (oral) | Cochrane reviews; RCTs vs placebo and vs alarm | Rapid reduction in wet nights; useful for short-term need (camps, sleepovers) | Hyponatremia, headache, GI upset; high relapse off treatment | moderate | First-line pharmacotherapy; intranasal form not recommended for enuresis |
| Anticholinergics (oxybutynin) | Small RCTs; observational data in non-monosymptomatic enuresis | Improvement when detrusor overactivity contributes; useful add-on to desmopressin | Constipation (paradoxically worsens enuresis), dry mouth, cognitive effects, urinary retention | low | Best for non-monosymptomatic enuresis with documented OAB |
| Imipramine | Cochrane review; older RCTs | Modest reduction in wet nights | Cardiotoxicity, anticholinergic effects, overdose lethality | low | Reserved for treatment-resistant cases; baseline EKG; secure supply |
| Constipation management | Observational and small RCT data | Resolves enuresis in subset; improves response to other therapies | Loose stools with overdosing of laxatives | moderate | Mandatory first step when constipation is present |
| Adenotonsillectomy for OSA | Cohort and small RCT data | Resolution or improvement of enuresis in OSA-positive children | Surgical risk; not all OSA-positive children respond | low | Refer when OSA features are present |
| Combination alarm + desmopressin | Small RCTs and meta-analyses | Higher initial response than either alone in selected patients | Combined adverse-effect profile; cost and complexity | low | Consider in refractory cases with both polyuria and high arousal threshold |
Both first-line therapies carry meaningful, well-characterized adverse effect profiles, and the broader evidence base — though long-standing — is dominated by short-duration trials with heterogeneous outcome definitions. The harms picture is dominated by desmopressin-related hyponatremia and alarm-related family burden.15-17
Common adverse effects
- Desmopressin: headache, abdominal pain, nausea, nasal stuffiness with the rarely used intranasal form.9,17
- Enuresis alarm: family sleep disruption, frustration, premature discontinuation.10
- Anticholinergics: constipation (which can worsen enuresis), dry mouth, blurred vision, behavioral changes.7
- Imipramine: anticholinergic effects, sedation, weight changes, orthostasis.16
Serious or rare adverse effects
- Hyponatremic seizures with desmopressin, particularly with intranasal use, excessive fluid intake, or intercurrent illness with vomiting.17
- Imipramine cardiotoxicity in therapeutic use (QT prolongation, conduction delays) and lethality in overdose.16
- Anticholinergic urinary retention and rare hyperthermia in hot environments.7
Monitoring and discontinuation
- Periodic reassessment of fluid restriction, weight, and adherence is required for desmopressin; clinicians should screen for new vomiting or polydipsia at every visit.17
- Baseline and periodic EKGs are commonly recommended for imipramine; supply must be secured at home.16
- Structured tapering of desmopressin (rather than abrupt stop) reduces but does not eliminate relapse.9,16
- Alarm therapy requires sustained engagement; abandoning therapy in the first 2 weeks is the most common cause of failure.10
Limitations of the evidence base
- Most pharmacologic and behavioral trials report short follow-up (often 3-6 months), limiting confidence in long-term efficacy and relapse estimates.16
- Many trials enroll heterogeneous populations without separating monosymptomatic from non-monosymptomatic enuresis, complicating clinical extrapolation.16
- Outcome definitions vary (number of wet nights per 2 weeks, percent reduction, ICCS response categories), reducing comparability across studies.16
- Adolescent and treatment-resistant populations are under-studied compared with school-age children.16
Treatment selection shifts substantially in younger children, adolescents, those with developmental disabilities, and those with comorbid medical conditions. The diagnostic threshold itself depends on developmental age, not chronological age.11
Preschool-age children
- Children below age 5 (chronological or developmental) do not meet criteria; bedwetting in this group is developmentally typical and warrants reassurance.11
- Avoid pharmacotherapy in children younger than 5 years; behavioral measures and toileting routine suffice.7
Adolescents
- Persistence into adolescence is associated with higher rates of psychiatric comorbidity (anxiety, depression, low self-esteem) and merits a broader behavioral health assessment.13
- Desmopressin and the enuresis alarm remain first-line; combination therapy is more often required.16
- Imipramine becomes a more reasonable consideration in adolescents than in young children given improved supply control, but requires baseline EKG and shared decision-making about cardiotoxicity.16
Neurodevelopmental disabilities
- Children with autism spectrum disorder, intellectual disability, or global developmental delay are at higher risk and may not meet the developmental-age threshold.2
- Toileting programs adapted to developmental level (visual schedules, structured timing) form the mainstay; alarm therapy can succeed when adapted to the child's sensory profile.2
- Constipation is especially common and should be screened for explicitly.2,7
ADHD:
- Comorbid ADHD predicts poorer alarm adherence; treating ADHD optimally often improves enuresis treatment outcomes indirectly.6
- Methylphenidate is not a treatment for enuresis but generally does not worsen it; rare worsening has been reported.6,15
Perinatal and adult considerations
- Approximately 1-2% of adults have persistent or recurrent nocturnal enuresis; evaluation parallels pediatric workup with added attention to OSA, alcohol use, diabetes, and prostate disease in men.1,7
- Desmopressin is used off-label in selected adults; hyponatremia risk rises with age and concurrent medications.17
Comorbid medical illness
- Sickle cell disease, diabetes mellitus, diabetes insipidus, and chronic kidney disease all impair urine concentration and warrant disease-specific management before symptomatic enuresis treatment.7
- OSA workup and treatment can resolve enuresis without further intervention in affected children.14
Cultural and contextual factors
- Family beliefs about wetting (punitive responses, attributions of laziness) strongly affect outcome; explicit, blame-free education is part of treatment in every culture.13
- Sleepovers, camp, and school trips are common reasons families seek treatment and may justify short-term desmopressin even when the alarm is the longer-term plan.9
The natural history of primary monosymptomatic nocturnal enuresis is favorable, with steady spontaneous remission through childhood and adolescence. Treatment shortens the time to dryness but the eventual outcome for most untreated children is also continence.1,3
Spontaneous remission
- Approximately 15% of untreated children with nocturnal enuresis become dry each year.3
- By late adolescence, fewer than 1-2% remain symptomatic.1,3
Response to treatment
- Enuresis alarm produces full response in roughly 50-70% with appropriate use, with sustained dryness in 40-50% of responders after discontinuation.10,16
- Desmopressin produces full response in approximately 30% and partial response in another 40%, with relapse in 60-70% on abrupt withdrawal; structured tapering reduces but does not eliminate relapse.9,16
- Combination therapy may improve response rates in selected children, particularly those with mixed polyuria and bladder dysfunction features.16
Predictors of poorer outcome
- Daytime symptoms (non-monosymptomatic enuresis).7
- High frequency of wet nights (>5/week) at baseline.16
- Comorbid ADHD or behavioral disorder.6
- Strong family history with late resolution in relatives.5
- Untreated constipation or OSA.7,14
Functional outcome
Enuresis itself is rarely an emergency, but two adverse drug effects (desmopressin-induced hyponatremia and imipramine toxicity) and two underlying conditions (new-onset diabetes and spinal cord pathology) deserve emergency-level vigilance.7,17-18
Drug-related emergencies
- Hyponatremic seizures with desmopressin: present with headache, vomiting, lethargy, confusion, or seizure; hold desmopressin during any febrile or vomiting illness and reinforce fluid restriction at every visit.17
- Imipramine overdose: presents with tachycardia, hypotension, QRS widening, seizures, and coma; activated charcoal if recent and sodium bicarbonate for QRS prolongation; secure supply at home.16
Underlying-condition emergencies
- New-onset polyuria with weight loss, polydipsia, or ill appearance warrants urgent evaluation for diabetes mellitus including new-onset type 1 with diabetic ketoacidosis risk.7
- Acute change in continence with new lower-extremity weakness, gait change, or back pain warrants urgent neurologic evaluation for cord compression or tethered cord.7
Safety-relevant comorbidities
- Suicidal ideation in adolescents with chronic enuresis warrants direct assessment, particularly when shame, bullying, or family conflict are prominent.13
- Child maltreatment, including sexual abuse, should be considered in unexplained secondary enuresis with behavioral regression; document concerns and follow mandated reporting standards.2
Do not use intranasal desmopressin for the treatment of nocturnal enuresis; the FDA contraindicated this indication in 2007 after reports of severe hyponatremia and death.17
Enuresis is a settled diagnostic entity, but several management questions remain genuinely contested.
- Whether to treat at all in younger school-age children: some clinicians argue that given high spontaneous remission, active treatment before age 7 risks medicalizing a developmental variant, while others counter that earlier intervention reduces psychosocial harm.3,7
- Optimal sequencing of alarm versus desmopressin: head-to-head trials show alarms produce more durable response and desmopressin produces faster response, and guidelines split on which to recommend first based on family priorities.7,9-10
- Role of combination therapy: combining alarm with desmopressin may improve initial dry-night rates but the magnitude and durability of benefit over monotherapy remain uncertain.16
- Anticholinergics for nonresponders: the evidence base for oxybutynin and similar agents in nocturnal enuresis without daytime overactive bladder symptoms is limited.[CITE NEEDED]
- Imipramine's place in modern practice: efficacy is established but cardiotoxicity in overdose has pushed it out of first-line use in most jurisdictions, and guidelines disagree on whether it retains a niche role.16
- Sleep-disordered breathing as a driver: adenotonsillectomy resolves enuresis in a meaningful subset of children with obstructive sleep apnea, but routine polysomnography in enuresis is not endorsed.14
- ICD-11 versus DSM-5-TR thresholds: the two systems differ slightly in frequency and duration criteria, and case ascertainment in epidemiologic studies varies accordingly.11-12
- DSM-5-TR requires a chronological age of at least 5 years (or equivalent developmental level) for the diagnosis of enuresis.11
- The DSM-5-TR frequency threshold is at least twice weekly for three consecutive months, or clinically significant distress or impairment.11
- Primary enuresis means continence has never been sustained for six months; secondary enuresis means relapse after a dry interval of at least six months.1,11
- Subtypes are nocturnal only, diurnal only, and nocturnal and diurnal combined.11
- Monosymptomatic nocturnal enuresis lacks any daytime lower urinary tract symptoms; nonmonosymptomatic enuresis includes urgency, frequency, or daytime incontinence and is managed differently.1,7
- Pathophysiology in monosymptomatic nocturnal enuresis involves nocturnal polyuria, reduced functional bladder capacity, and high arousal threshold.8
- First-degree family history is present in roughly two-thirds of children with primary nocturnal enuresis.5
- ADHD is the most common comorbid psychiatric condition in enuresis.6
- Enuresis alarms produce the highest long-term cure rates; desmopressin produces faster but less durable response.9-10
- Desmopressin requires fluid restriction in the evening because of the risk of hyponatremic seizures, particularly with the intranasal formulation, which is no longer indicated for nocturnal enuresis in the United States.17
- Imipramine is effective but cardiotoxic in overdose, limiting first-line use; baseline EKG is required before initiation.16
- Obstructive sleep apnea is an underrecognized cause of secondary nocturnal enuresis and may resolve with adenotonsillectomy.14
- Constipation should be screened for and treated before pharmacotherapy in any child with enuresis.7
- Spontaneous remission of nocturnal enuresis occurs in approximately 15% of affected children per year after age 5.3
No external funding. No conflicts of interest declared. Peer-review status: pending.
- 1.Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the Standardization Committee of the International Children's Continence Society. J Urol. 2014;191(6):1863-1865.e13. doi:10.1016/j.juro.2014.01.110. PMID: 24508614.PMID: 24508614doi:10.1016/j.juro.2014.01.110
- 2.TextbookSadock BJ, Sadock VA, Ruiz P. Kaplan and Sadock's Synopsis of Psychiatry. 12th ed. Philadelphia: Wolters Kluwer; 2022.
- 3.Forsythe WI, Redmond A. Enuresis and spontaneous cure rate: study of 1129 enuretics. Arch Dis Child. 1974;49(4):259-263. doi:10.1136/adc.49.4.259. PMID: 4830115.PMID: 4830115doi:10.1136/adc.49.4.259
- 4.Sureshkumar P, Jones M, Cumming R, Craig J. A population based study of 2,856 school-age children with urinary incontinence. J Urol. 2009;181(2):808-15. doi:10.1016/j.juro.2008.10.044. PMID: 19110268.PMID: 19110268doi:10.1016/j.juro.2008.10.044
- 5.von Gontard A, Heron J, Joinson C. Family history of nocturnal enuresis and urinary incontinence: results from a large epidemiological study. J Urol. 2011;185(6):2303-2306. doi:10.1016/j.juro.2011.02.040. PMID: 21511300.PMID: 21511300doi:10.1016/j.juro.2011.02.040
- 6.Baeyens D, Roeyers H, Hoebeke P, Verté S, Van Hoecke E, Vande Walle J. Attention deficit/hyperactivity disorder in children with nocturnal enuresis. J Urol. 2004;171(6 Pt 2):2576-9. doi:10.1097/01.ju.0000108665.22072.b2. PMID: 15118422.PMID: 15118422doi:10.1097/01.ju.0000108665.22072.b2
- 7.Vande Walle J, Rittig S, Bauer S, Eggert P, Marschall-Kehrel D, Tekgul S; American Academy of Pediatrics; European Society for Paediatric Urology; European Society for Paediatric Nephrology; International Children's Continence Society. Practical consensus guidelines for the management of enuresis. Eur J Pediatr. 2012;171(6):971-983. doi:10.1007/s00431-012-1687-7. PMID: 22362256.PMID: 22362256doi:10.1007/s00431-012-1687-7
- 8.Nevéus T. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26(8):1207-14. doi:10.1007/s00467-011-1762-8. PMID: 21267599.PMID: 21267599doi:10.1007/s00467-011-1762-8
- 9.Systematic reviewGlazener CM, Evans JH. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev. 2002;(3):CD002112. doi:10.1002/14651858.CD002112. PMID: 12137645.PMID: 12137645doi:10.1002/14651858.CD002112
- 10.Systematic reviewGlazener CM, Evans JH, Peto RE. Alarm interventions for nocturnal enuresis in children. Cochrane Database Syst Rev. 2005;(2):CD002911. doi:10.1002/14651858.CD002911.pub2. PMID: 15846643.PMID: 15846643doi:10.1002/14651858.CD002911.pub2
- 11.TextbookAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text rev. Washington, DC: American Psychiatric Association Publishing; 2022.
- 12.TextbookWorld Health Organization. International Classification of Diseases, 11th Revision (ICD-11). Geneva: World Health Organization; 2019.
- 13.Joinson C, Heron J, Emond A, Butler R. Psychological problems in children with bedwetting and combined (day and night) wetting: a UK population-based study. J Pediatr Psychol. 2007;32(5):605-16. doi:10.1093/jpepsy/jsl039. PMID: 17071625.PMID: 17071625doi:10.1093/jpepsy/jsl039
- 14.Brooks LJ, Topol HI. Enuresis in children with sleep apnea. J Pediatr. 2003;142(5):515-8. doi:10.1067/mpd.2003.158. PMID: 12756383.PMID: 12756383doi:10.1067/mpd.2003.158
- 15.TextbookStahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge: Cambridge University Press; 2021.
- 16.Systematic reviewCaldwell PHY, Sureshkumar P, Wong WCF. Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database Syst Rev. 2016;(1):CD002117. doi:10.1002/14651858.CD002117.pub2. PMID: 26789925.PMID: 26789925doi:10.1002/14651858.CD002117.pub2
- 17.RegulatoryU.S. Food and Drug Administration. FDA information for healthcare professionals: desmopressin acetate (marketed as DDAVP nasal spray, DDAVP rhinal tube, DDAVP, DDVP, Minirin, and Stimate nasal spray). Silver Spring, MD: U.S. Food and Drug Administration; 2007.
- 18.Systematic reviewBarroso U Jr, Tourinho R, Lordêlo P, Hoebeke P, Chase J. Electrical stimulation for lower urinary tract dysfunction in children: a systematic review of the literature. Neurourol Urodyn. 2011;30(8):1429-36. doi:10.1002/nau.21140. PMID: 21717502.PMID: 21717502doi:10.1002/nau.21140
More on these topics
Encopresis: Diagnosis, Evaluation, and Treatment in Children
A clinical reference on encopresis in children covering DSM-5-TR criteria, retentive versus nonretentive subtypes, evaluation, and a stepwise disimpaction-maintenance-behavioral treatment plan.
Elimination DisordersChild & Adolescent PsychiatryEncopresisElimination Disorders (Enuresis and Encopresis): Diagnosis and Clinical Management
A clinical guide to enuresis and encopresis in children, covering DSM-5-TR criteria, evaluation, behavioral and pharmacologic management, and prognosis.
EnuresisEncopresisChild & Adolescent PsychiatryPyromania: Clinical Features, Differential Diagnosis, and Evidence-Based Management
A practical chapter on pyromania — DSM-5-TR criteria, the difference between pyromania and arson, and what the thin evidence base supports for treatment.
Child & Adolescent PsychiatryPyromaniaDifferential DiagnosisConduct Disorder: Diagnosis, Assessment, and Evidence-Based Management
A clinical reference on conduct disorder covering DSM-5-TR criteria, the limited prosocial emotions specifier, assessment, and evidence-based treatment.
Conduct DisorderChild & Adolescent PsychiatryOppositional Defiant Disorder
Clinical chapter on Oppositional Defiant Disorder for medical students and psychiatry residents: DSM-5-TR criteria, dimensions, differential, and evidence-based treatment.
Oppositional Defiant DisorderChild & Adolescent PsychiatryDisruptive, Impulse-Control, and Conduct Disorders: A Clinical Overview
A clinical reference on oppositional defiant disorder, conduct disorder, intermittent explosive disorder, kleptomania, and pyromania across the lifespan.
Conduct DisorderChild & Adolescent PsychiatryIntermittent Explosive DisorderDisruptive Mood Dysregulation Disorder (DMDD): Diagnosis, Differential, and Management
A clinical reference on DMDD — the DSM-5-TR childhood diagnosis built to curb pediatric bipolar overdiagnosis, with assessment and treatment guidance.
Differential DiagnosisChild & Adolescent PsychiatryDisruptive Mood Dysregulation DisorderSelective Mutism: Diagnosis, Differential, and Evidence-Based Treatment
A clinical reference on selective mutism — DSM-5-TR criteria, anxiety-spectrum framing, assessment, and graded behavioral and pharmacologic treatment.
Anxiety DisordersPsychopharmacologyChild & Adolescent Psychiatry